PrecivityAD™ Blood Test’s Reach Expands to Europe and California Following Initial Launch; Test Detects Alzheimer’s Disease Pathology
Building on the first stage of its successful launch in the United States, C₂N Diagnostics announces that the PrecivityAD™ blood test has achieved the CE Mark from the European Union (EU) as well as approval for its lab to conduct tests for California patients.